Market Research Logo

Global Hepatitis B and C Diagnostics Market 2016-2020

Global Hepatitis B and C Diagnostics Market 2016-2020

About Hepatitis B and Hepatitis C

Hepatitis B diagnostic tests include HBV serologic tests, molecular deoxyribonucleic acid (DNA) tests, histology tests, and laboratory tests. HBV serologic tests involve the measurement of antigens and antibodies. Hepatitis C diagnostic tests include anti-HCV serologic test, HCV recombinant immunoblot assay (RIBA) antibody test, and HCV molecular ribonucleic acid (RNA) testing. Anti-HCV is the serologic test used for screening.

Technavio’s analysts forecast the global hepatitis B and C diagnostics market to grow at a CAGR of 6.35% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hepatitis B and C diagnostics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of immunodiagnostics and nucleic acid test (NAT) instruments and consumables to hospitals, diagnostic centers, and research institutes.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hepatitis B and C Diagnostics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Abbott Diagnostics
  • Roche Diagnostics
  • Siemens Healthcare
  • QIAGEN
Other prominent vendors
  • Affymetrix
  • Allele Biotechnology
  • Axis-Shield
  • Becton Dickinson
  • bioMérieux
  • Cepheid
  • Chembio Diagnostics
  • DiaMetra
  • DiaSorin
  • Enzo Life Sciences
  • Hologic
  • ImmunoDX
  • MedMira
  • OraSure Technologies
  • Quest Diagnostics
  • Quidel
  • Randox Laboratories
  • Vela Diagnostics
  • Vital Diagnostics
  • ZEUS Scientific
Market driver
  • Strategies of healthcare organizations toward simplifying the diagnostic process
  • For a full, detailed list, view our report
Market challenge
  • Regulatory and reimbursement hurdles limit the adoption rate
  • For a full, detailed list, view our report
Market trend
  • Advent of immunosensors in the HBV and HCV diagnostic tests
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hepatitis B and C Diagnostics Market 2016-2020

Technavio recognizes the following companies as the key players in the global hepatitis B and C diagnostics market: Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare, and QIAGEN.

Other Prominent Vendors in the market are: Affymetrix, Allele Biotechnology, Axis-Shield, Becton Dickinson, bioMérieux, Cepheid¸ Chembio Diagnostics, DiaMetra, DiaSorin, Enzo Life Sciences, Hologic, ImmunoDX, MedMira, OraSure Technologies, Quest Diagnostics, Quidel, Randox Laboratories, Vela Diagnostics, Vital Diagnostics, and ZEUS Scientific.

Commenting on the report, an analyst from Technavio’s team said: “One of the key trends for market growth will be high demand for biomarker-based tests. Sophisticated R&D for proteomics, nucleic acid expression, and genome sequencing has led to the emergence of molecular biomarkers. Biomarkers are proteins, genes, hormones, and other molecular entities that detect the absence or presence of a disease. Technological advancements are driving manufacturers to develop assays that identify biomarkers in high-growth clinical areas such as infectious diseases, including hepatitis and retroviruses. Biomarker-based tests will likely replace conventional drug therapeutics and account for increased revenue and sales from personalized test devices. To better reach the market, companies are developing cost-effective biomarker-based tests. Increased approvals for devices and rise in product launches are expected to propel market growth during the forecast period.”

According to the report, increase in demand for automation and system integration will be a key driver for market growth. An increasing number of consumers are opting for fully automated and semi-automated systems over conventional (manual) systems. Laboratory automation increases productivity, with high test volumes handled efficiently by few people. This type of automation helps when there is a shortage of trained technicians. Also, automated systems provide precise results, which are otherwise difficult to achieve. Vendors are developing devices and systems that help integrate laboratory applications. For instance, the COBAS 6000 modular platform by Roche Diagnostics offers optimum efficiency and consolidation in medium- and high-volume laboratories. The company estimates that 95% of the workload is consolidated into this system, which allows for an upgrade in workload. The system's software and graphical user interface (GUI) permit streamlined information management and offer solutions ranging from remote test ordering to sophisticated result analysis. Integrated systems with enhanced automation and efficiency are expected to fuel market growth during the forecast period.

Further, the report states that one of the challenges for the market will be regulatory and reimbursement hurdles that limit the adoption rate. Validation studies and guidelines help companies to register their diagnostic testing devices and assays with regulatory authorities. The process, however, is time-consuming, requiring documentation at every stage and real-time data collection. The studies require real-time sample collections or samples from biobanks. For infectious diseases such as hepatitis B and C infections, the lack of such sample storage facilities makes validation studies difficult for manufacturers. Also, there is no clarity on the reimbursements for diagnostic devices globally. To reduce costs, countries such as the US, Australia, and few countries in EU are decreasing the reimbursement amount for diagnostic testing devices. These factors restrain market growth. The lack of reimbursement or insufficient reimbursement severely hinders the adoption of these devices, especially in developed countries.

Companies Mentioned

Abbott Diagnostics, Roche Diagnostics, Siemens Healthcare, QIAGEN, Affymetrix, Allele Biotechnology, Axis-Shield, Becton Dickinson, bioMérieux, Cepheid¸ Chembio Diagnostics, DiaMetra, DiaSorin, Enzo Life Sciences, Hologic, ImmunoDX, MedMira, OraSure Technologies, Quest Diagnostics, Quidel, Randox Laboratories, Vela Diagnostics, Vital Diagnostics, ZEUS Scientific.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Hepatitis B and C diagnostics: An overview
    • Hepatitis B disease overview
      • Table Possible outcomes of HBV infection
      • Table Concentration of HBV in several body fluids
      • Table Pathway of hepatitis B progression
      • Table Disease progression of hepatitis B
      • Table Significance of serological markers
      • Table Types of hepatitis B diagnostic tests
      • Table Diagnostic strategies for HBV
      • Table Interpretation of serological markers
      • Table Endemicity pattern of hepatitis B across different regions
      • Table Medical cost for chronic viral hepatitis
    • Hepatitis C disease overview
      • Table Progression of hepatitis C
      • Table Risk factors for hepatitis transmission
      • Table Screening tests for hepatitis C infection
      • Table Medical cost for hepatitis C and related infections
  • Reimbursement scenario: An overview
    • Table Reimbursement perspectives of healthcare entities
  • Market landscape
    • Market overview
      • Table Global hepatitis B and C diagnostics market analysis: Developed and emerging markets
      • Table Snapshot of global hepatitis B and C diagnostics market
    • Global hepatitis B and C diagnostics market overview
      • Table Global hepatitis B and C diagnostics market 2025-2020 ($ billions)
      • Table Opportunity analysis of hepatitis B and C diagnostics market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by procedure
    • Table Global hepatitis B and C diagnostics market by procedure 2015-2020
    • Table Global hepatitis B and C diagnostics market by procedure 2015 ($ billions)
    • Table Global hepatitis B and C diagnostics market by procedure: Lifecycle analysis 2015
    • Immunodiagnostics
    • Immunofluorescence
    • Instruments
    • Reagents
    • Global hepatitis B and C immunodiagnostics market overview
      • Table Global hepatitis B and C immunodiagnostics market 2025-2020 ($ billions)
      • Table Opportunity analysis of immunodiagnostics
      • Table Global hepatitis B and C immunodiagnostics market segmentation by product type 2015
    • NAT
    • Global hepatitis B and C NAT market overview
      • Table Global hepatitis B and C NAT market 2025-2020 ($ millions)
      • Table Global hepatitis B and C NAT market segmentation by product type 2015
      • Table Opportunity analysis of global hepatitis B and C NAT market
      • Table Global hepatitis B and C diagnostics market segmentation by procedure 2025-2020 ($ millions)
      • Table Global hepatitis B and C diagnostics market segmentation by procedure 2025-2020 (%)
      • Table Global hepatitis B and C diagnostics market segmentation: Impact analysis 2015-2020
  • Market segmentation by disease
    • Table Global hepatitis B and C diagnostics market by disease type 2015-2020
    • Table Global hepatitis B and C diagnostics market by disease type 2015
    • Table Global hepatitis B and C diagnostics market by disease type: Lifecycle analysis 2015
    • Hepatitis B
      • Table Acute hepatitis B infection by demography 2015
      • Table Chronic hepatitis B infection by demography 2015
    • Global hepatitis B diagnostics market overview
      • Table Procurement of hepatitis B diagnostic kits by WHO 2015
      • Table Global hepatitis B diagnostics market 2015-2020 ($ millions)
      • Table Opportunity analysis of global hepatitis B diagnostics market
    • Hepatitis C
      • Table Prevalence rates of hepatitis C across different regions 2015
      • Table Treatment cost of hepatitis C-related infections
    • Global hepatitis C diagnostics market overview
      • Table Procurement of hepatitis C diagnostic kits by WHO 2015
      • Table Opportunity analysis of hepatitis C
      • Table Global hepatitis C diagnostics market 2015-2020 ($ billions)
      • Table Global hepatitis B and C diagnostics market by disease type 2015-2020 ($ millions)
      • Table Global hepatitis B and C diagnostics market by disease type 2015-2020 (%)
      • Table Global hepatitis B and C diagnostics segmentation by disease type
  • Geographical segmentation
    • Table Geographical hepatitis B and C diagnostics market 2015
    • Table Global hepatitis B and C diagnostics: Regional market lifecycle analysis
    • Table Global hepatitis B and C diagnostics market by geography 2015-2020
    • Table Global hepatitis B and C diagnostics market segmentation by geography 2015
    • Table Global hepatitis B and C diagnostics market by geography lifecycle analysis 2015
    • Hepatitis B and C diagnostics market in Americas
      • Table Hepatitis B and C diagnostics in Americas 2015
      • Table Prevalence data of hepatitis C in North America
      • Table Prevalence data of hepatitis C in Latin America
      • Table Hepatitis B and C diagnostics market in Americas 2015-2020 ($ billions)
    • Hepatitis B and C diagnostics market in EMEA
      • Table Prevalence data of hepatitis C in Europe
      • Table Hepatitis B and C diagnostics market in EMEA 2015-2020 ($ billions)
    • Hepatitis B and C diagnostics market in APAC
      • Table Prevalence rate of hepatitis B in APAC
      • Table Prevalence data of hepatitis C in APAC
      • Table Hepatitis B and C diagnostics market in EMEA 2015-2020 ($ billions)
      • Table Global hepatitis B and C diagnostics market by geography 2025-2020 ($ millions)
      • Table Global hepatitis B and C diagnostics market by geography 2025-2020 (%)
      • Table Global hepatitis B and C diagnostics market by geography
  • Market drivers
    • Growing demand for molecular diagnostics in the diagnosis of HBV and HCV
    • Strategies of healthcare organizations toward simplifying the diagnostic process
      • Table Strategies of healthcare organizations
    • Rising demand for POC diagnostics
      • Table Advantages of POC diagnostics
      • Table Recent and expected product launches of HCV POC diagnostic tests
    • Increase in demand for automation and system integration
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Presence of high undiagnosed individuals
      • Table Prevalence and diagnosis of HCV infections across developing countries 2015 (millions)
    • Limited detection capability and complexity of assays
      • Table Key factors affecting the adoption rates
    • Regulatory and reimbursement hurdles limit the adoption rate
    • Limitations of closed systems
      • Table Force field analysis of global hepatitis b and C diagnostics market
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Advent of immunosensors in the HBV and HCV diagnostic tests
    • Paradigm shift toward the use of hepatitis C core antigen test
      • Table Key advantages driving the adoption of HCV core antigen test
    • High demand for biomarker-based tests
      • Table Impact of trends on global hepatitis B and C diagnostics market 2015-2020
  • Vendor landscape
    • Competitive scenario
      • Table Key leading vendors ranking for instruments 2015
      • Table Presence of vendors in the global hepatitis B and C diagnostics market
    • Key news
  • Key vendor analysis
    • Abbott Diagnostics
      • Table Abbott Laboratories: Key business offerings
      • Table Abbott Diagnostics: Metric analysis
    • Roche Diagnostics
      • Table Hoffmann-La Roche: Business segmentation by revenue 2015
      • Table Roche Diagnostics: Products and description
      • Table Roche Diagnostics: Business segmentation by revenue 2015
      • Table Roche Diagnostics: Metric analysis
    • Siemens Healthcare
      • Table Siemens Healthcare: Various tests available in multiple diseases
      • Table Siemens Healthcare: Metric analysis
    • QIAGEN
      • Table QIAGEN: Metric analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report